Cargando…
Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
BACKGROUND: The status of the EGFR and HER2-neu genes has not been fully defined in ovarian cancer. An integrated analysis of both genes could help define the proportion of patients that would potentially benefit from targeted therapies. METHODS: We determined the tumour mutation status of the entir...
Autores principales: | Vermeij, Joanna, Teugels, Erik, Bourgain, Claire, Xiangming, Ji, in 't Veld, Peter, Ghislain, Vanessa, Neyns, Bart, De Grève, Jacques |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266762/ https://www.ncbi.nlm.nih.gov/pubmed/18182111 http://dx.doi.org/10.1186/1471-2407-8-3 |
Ejemplares similares
-
Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector
por: Vermeij, J, et al.
Publicado: (2001) -
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
por: de Graeff, P, et al.
Publicado: (2009) -
Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015) -
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
por: Umelo, Ijeoma, et al.
Publicado: (2015) -
Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma (GBC)
por: Das, Chhanda, et al.
Publicado: (2021)